Literature DB >> 9424086

Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype.

T Kawakami1, H Ihn, W Xu, E Smith, C LeRoy, M Trojanowska.   

Abstract

Scleroderma fibroblasts exhibit numerous phenotypic differences when compared with healthy skin fibroblasts. Some of these differences, in particular overexpression of collagen type I and other extracellular matrix proteins, parallel the effect of transforming growth factor-beta (TGF-beta) on dermal fibroblasts, suggesting that the scleroderma fibroblast phenotype may result from activation of autocrine TGF-beta signaling. To test this hypothesis we examined the role of TGF-beta Type I and Type II receptors in regulating collagen type I transcription. We have shown that overexpression of either Type I or Type II receptors significantly (3-4-fold) increases alpha2 (I) collagen promoter activity in transient transfection assays in dermal fibroblasts. Addition of anti-TGF-beta antibody abolished, whereas addition of plasmin enhanced, the stimulatory effect of receptor overexpression on collagen promoter activity, suggesting that this effect depends on autocrine TGF-beta. Moreover, these cotransfection experiments indicated that expression levels of TGF-beta receptors is a limiting factor in the autocrine regulation of collagen type I transcription by TGF-beta. Comparison of the TGF-beta receptor Type I and Type II mRA expression levels in scleroderma and normal fibroblasts have indicated elevated expression (2-fold) of both receptor types in scleroderma cells, which correlated with increased binding of TGF-beta. Significantly, elevated TGF-beta receptor levels correlated with elevated alpha2 (I) collagen mRNA levels. These results suggest that the elevated production of collagen type I by scleroderma fibroblasts results from overexpression of TGF-beta receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9424086     DOI: 10.1046/j.1523-1747.1998.00073.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  60 in total

Review 1.  The promise of transcription profiling for understanding the pathogenesis of scleroderma.

Authors:  D R Strehlow
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  The genetics of systemic sclerosis.

Authors:  Randall W Johnson; Monty B Tew; Frank C Arnett
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 4.  Apoptosis and myofibroblasts in the pathogenesis of systemic sclerosis.

Authors:  Eugene Kissin; Joseph H Korn
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 5.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

6.  Acid sphingomyelinase deficiency contributes to resistance of scleroderma fibroblasts to Fas-mediated apoptosis.

Authors:  Glady Hazitha Samuel; Stefania Lenna; Andreea M Bujor; Robert Lafyatis; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2012-06-26       Impact factor: 4.563

7.  Mast cells, extracellular matrix components, TGFbeta isoforms and TGFbeta receptor expression in labial salivary glands in systemic sclerosis.

Authors:  G I Mason; J Hamburger; J B Matthews
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

8.  Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration?

Authors:  Christopher G Elliott; Douglas W Hamilton
Journal:  J Cell Commun Signal       Date:  2011-04-19       Impact factor: 5.782

9.  Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis.

Authors:  Meredith L Sosulski; Rafael Gongora; Carol Feghali-Bostwick; Joseph A Lasky; Cecilia G Sanchez
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-05-01       Impact factor: 6.053

10.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.